Effects of somatostatin-28 on plasma glucose-dependent insulinotropic polypeptide and serum insulin concentrations.
Faulkner
A
A
Hannah Research Institute, Ayr, UK.
Martin
P A
PA
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000097:blood* / Q000378:metabolism; D005934:Glucagon; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood* / Q000378:metabolism; D000078790:Insulin Secretion; D010446:Peptide Fragments / Q000008:administration & dosage; D012756:Sheep; D013004:Somatostatin / Q000008:administration & dosage / Q000494:pharmacology*; D053561:Somatostatin-28
D001786:Blood Glucose; D007328:Insulin; D010446:Peptide Fragments; C061970:glucagon-like peptide 1 (7-36); D013004:Somatostatin; D005749:Gastric Inhibitory Polypeptide; D004763:Glucagon-Like Peptides; D053561:Somatostatin-28; D052216:Glucagon-Like Peptide 1; D005934:Glucagon